Regeneron Pharmaceuticals, Inc.

Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron: Is The Market Undervaluing Its Growth Potential

At the end of October, Regeneron Pharmaceuticals, Inc. will report its results for Q3. As a reminder, REGN's Q2 revenue rose 18.8% quarter-on-quarter and 16.6% YoY to $4.29 billion, primarily due to the strong performance of Dupixent. On October 12, Regeneron reported positive Phase 3 OPTIMA results, demonstrating sustained Pasatru efficacy in reducing new HO lesions and disease flare-ups in people with FOP.

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

Regeneron's leading weight-loss candidate could offer patients an option with fewer side effects. The company has another investigational weight-loss medicine designed to help preserve lean muscle mass.

Frank Rimerman Advisors LLC Acquires 876 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Insider Sells $3,204,386.90 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) insider Andrew Murphy sold 4,147 shares of the stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at

Regeneron’s Murphy sells $3.2 million in stock under plan (NASDAQ: REGN)

What happened Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 shares on 10/14/2026. The shares sold for $753.76 to $781.47 each and brought in about $3.20 million, according to the Form 4. The filing says the trades were made under a Rule 10b5-1 trading plan. The same filing shows

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Regeneron's revenue is growing at a good clip despite declining Eylea sales. Dupixent is the main reason behind recent strong financial results.

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment